Delivery Order SPE2DB20D3101-SPE2DB25FRTS1
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $12,151.38 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,979.13 for Dupixent 300 mg/2 mL pen injectors on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price contract, which has no set-aside designation, represents a competitively awarded procurement supporting federal medical supply needs. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $31,503.39 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This competitively awarded, firm fixed price contract is scheduled for completion by August 15, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $12,957.54 under firm fixed price terms. The delivery order, which represents a child contract under a larger vehicle, has an ultimate completion date of August 25, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This award was made through competitive procedures...
- The Defense Logistics Agency awarded a delivery order valued at $53,836.52 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price, competitively awarded delivery order represents a pharmaceutical supply fulfillment under the company's broader federal contract portfolio. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $12,465.70 to supply Dupixent 300 mg/2 mL pen injectors on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, non-set-aside contract represents a routine pharmaceutical delivery under the company's existing indefinite delivery vehicle with DLA. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $35,657.00 to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract specifies a place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $10,503.00 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pen injectors. This competitively awarded, firm fixed-price contract was issued on July 28, 2025, with an ultimate completion date of July 29, 2025, and will be performed in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting AmerisourceBergen's capability to compete openly for federal pharmaceutical procurement...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRTS1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $18,140.12 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 27, 2025, with completion scheduled for August 28, 2025. This firm fixed-price, non-set-aside contract was awarded competitively and represents a single delivery order fulfillment under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters and primary distribution center. This award is a child contract issued under AmerisourceBergen's comprehensive Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The IDC serves as a global pharmaceutical support vehicle enabling AmerisourceBergen to supply pharmaceutical products and medical supplies to military healthcare programs and other federal healthcare systems. Dupixent, a specialty biologic medication used for conditions such as atopic dermatitis and asthma, represents the type of specialized pharmaceutical commodity delivered through this strategic contract vehicle that supports Defense Health Agency, U.S. Coast Guard, and other government healthcare customers worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.1k | 8/27/25 |